<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110883">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823965</url>
  </required_header>
  <id_info>
    <org_study_id>LLOMD</org_study_id>
    <nct_id>NCT01823965</nct_id>
  </id_info>
  <brief_title>Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the prospective monocentric open label trial patients with diabetic macular edema will be
      treated with intravitreal injections of ranibizumab given for 3 months then with laser grid
      at month 4. During follow-up a ranibizumab injection will be performed every 2 months in
      case of best-corrected visual acuity decreased more than 5 letters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Number of intravitreal injections of ranibizumab</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>best-corrected visual acuity</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <arm_group_label>ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes mellitus (1 or2)

          -  decreased vision from Diabetic Macular Edema (study eye Best Corrected Visual
             Acuity&lt;69 letters using E.T.D.R.S testing)

          -  macular edema

        Exclusion Criteria:

          -  history of severe cardiac disease

          -  stroke within 12 months

          -  intraocular inflammation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>michele BOISSONNOT</last_name>
    <phone>0549444891</phone>
    <email>michele.boissonnot@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KATIA GOUROU</last_name>
      <phone>0549443283</phone>
      <email>katia.gourou@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>April 3, 2013</lastchanged_date>
  <firstreceived_date>March 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
